Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in
cancer treatment. It is based on genetically modified T cells to express a CAR, which …

An emerging approach for treating cancer involves programming patient-derived T cells with
genes encoding disease-specific chimeric antigen receptors (CARs), so that they can …

CAR-T-cell therapy against MM currently shows promising results, but usually with serious
toxicities. CAR-NK cells may exert less toxicity when redirected against resistant myeloma …

BACKGROUND Chimeric antigen receptor (CAR) T cell immunotherapy has resulted in
complete remission (CR) and durable response in highly refractory patients. However …

Transposons are mobile genetic elements evolved to execute highly efficient integration of
their genes into the genomes of their host cells. These natural DNA transfer vehicles have …

T cell modification with genes that encode chimeric antigen receptors (CAR-T cells) has
shown tremendous promise for the treatment of B cell malignancies. The successful …

While initial approaches to adoptive T cell therapy relied on the identification and expansion
of rare tumour-reactive T cells, genetic engineering has transformed cancer immunotherapy …

Chimeric antigen receptor (CAR)-redirected T lymphocytes are a promising
immunotherapeutic approach and object of pre-clinical evaluation for the treatment of acute …

Cancer is a major burden on the healthcare system, and new therapies are needed.
Recently, the development of immunotherapies, which aim to boost or use the immune …